Method of treating inflammation by administering human IL-1B antibodies
AssigneeUCB Pharma S.A.
InventorsAlastair David Griffiths Lawson, Andrew George Popplewell
Life of this patent
Estimating the term…
Abstract
The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1β, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
Claims20
A method for the treatment of inflammation mediated by IL-1β or associated with an increased level of IL-1β comprising administering to a patient suffering from such inflammation a pharmaceutically effective amount of a pharmaceutical composition, said composition comprising a neutralising antibody having specificity for human IL-1β, the antibody comprising a heavy chain and a light chain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:5 for CDR-H1, the sequence given in SEQ ID NO:6 for CDR-H2 and the sequence given in SEQ ID NO:7 for CDR-H3 and wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:8 for CDR-L1, the sequence given in SEQ ID NO:9 for CDR-L2 and the sequence given in SEQ ID NO:10 for CDR-L3, in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.
A method for the treatment of inflammation mediated by IL-1β or associated with an increased level of IL-1β comprising administering to a patient suffering from such inflammation a pharmaceutically effective amount of a pharmaceutical composition, said composition comprising a neutralising antibody having specificity for human IL-1β, having a heavy chain comprising the sequence given in SEQ ID NO:
- 3 and a light chain comprising the sequence given in SEQ ID NO:4.
A method for the treatment of inflammation mediated by IL-1β or associated with an increased level of IL-1β comprising administering to a patient suffering from such inflammation a pharmaceutically effective amount of a pharmaceutical composition, said composition comprising a neutralising antibody having specificity for human IL-1β, which antibody is a modified Fab fragment having a heavy chain comprising the sequence given in SEQ ID NO:
- 15 and a light chain comprising the sequence given in SEQ ID NO:20 and having at the C-terminal end of its heavy chain a modified hinge region containing one cysteine residue to which an effector or reporter molecule may be attached.
A method for the treatment of inflammation mediated by IL-1β or associated with an increased level of IL-1β comprising administering to a patient suffering from such inflammation a pharmaceutically effective amount of a pharmaceutical composition, said composition comprising a neutralising antibody having specificity for human IL-1β, which antibody is a modified Fab fragment having a heavy chain comprising the sequence given in SEQ ID NO:
- 15 and a light chain comprising the sequence given in SEQ ID NO:20 and having at the C-terminal end of its heavy chain a modified hinge region containing one cysteine residue to which an effector or reporter molecule is attached.
A method for the treatment of inflammation mediated by IL-1β or associated with an increased level of IL-1β comprising administering to a patient suffering from such inflammation a pharmaceutically effective amount of a pharmaceutical composition, said composition comprising a neutralising antibody having specificity for human IL-1β having a heavy chain comprising amino acid residue numbers 22 to 251 of the sequence given in SEQ ID NO:71 and a light chain comprising amino acid residue numbers 22 to 235 of the sequence given in SEQ ID NO:70 and having an effector or reporter molecule attached to the cysteine residue at the C-terminal end of the heavy chain.
Dependencies are inferred from the claim text.